Direct Oral Anticoagulants (DOACs) Device Market Projected For Strong Expansion Through 2030: Key Trends And Future Outlook
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Direct Oral Anticoagulants (DOACs) Device Market Poised To Hit $49.48 Billion By 2030 With A 8.5% CAGR
The direct oral anticoagulants (doacs) device market has experienced significant expansion in recent years. It is forecast to rise from $32.8 billion in 2025 to $35.69 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.8%. The growth observed in previous periods was driven by factors such as the limited access to doac monitoring equipment, the reliance on hospital-based coagulation assessments, the increasing incidence of atrial fibrillation and thrombotic conditions, the widespread adoption of oral anticoagulant treatments, and a heightened focus on patient safety and effective anticoagulation monitoring.
The market for direct oral anticoagulants (doacs) devices is projected to experience substantial expansion over the forthcoming years. This market is anticipated to reach a valuation of $49.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. Several factors are expected to fuel this growth during the projection period, including progress in portable and point-of-care device technologies, the integration of digital health platforms with cloud-based monitoring solutions, a growing preference for personalized anticoagulation management, the expansion of services in homecare and specialized clinics, and a rise in regulatory endorsements for new monitoring systems. Key trends anticipated during the forecast encompass a greater embrace of point-of-care doac monitoring devices, an increased application of factor Xa and direct thrombin inhibitor monitoring, heightened public awareness regarding stroke and thromboembolism prevention, the broadening of homecare and ambulatory monitoring options, and a reinforced emphasis on improving accuracy, sensitivity, and speed in testing.
Get A Free Sample Report With In-Depth Market Insights:
Direct Oral Anticoagulants (DOACs) Device Market Demand Drivers Opening New Revenue Streams
The expanding occurrence of cardiovascular conditions is projected to boost the growth of the direct oral anticoagulants (DOACs) device market in the future. Cardiovascular disorders encompass various ailments affecting the heart and blood vessels, frequently resulting in complications like heart attacks, strokes, or other circulatory issues. These disorders are escalating due to progressively inactive lifestyles, contributing to weight gain, heightened blood pressure, and a gradual decline in cardiovascular function. Direct oral anticoagulants (DOACs) assist in managing cardiovascular disorders by effectively reducing the likelihood of stroke and blood clots in individuals with atrial fibrillation, providing dependable anticoagulation without requiring regular blood tests. For example, in October 2024, data from the Centers for Disease Control and Prevention, a US-based government agency, indicated that in 2023, cardiovascular disease was responsible for 919,032 lives lost, representing one in every three deaths. Coronary heart disease continued to be the most common type of heart disease, and notably, approximately one in six cardiovascular disease fatalities affected adults younger than 65 years. Consequently, the rising occurrence of cardiovascular disorders is propelling the expansion of the direct oral anticoagulants (DOACs) device market.
Direct Oral Anticoagulants (DOACs) Device Market Segment Trends And Revenue Contributors
The direct oral anticoagulants (doacs) device market covered in this report is segmented –
1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors
2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases
3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications
4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users
Subsegments:
1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices
2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate
Direct Oral Anticoagulants (DOACs) Device Market Trends Powering Strategic Industry Growth
Leading companies within the direct oral anticoagulants (DOACs) device market are concentrating on developing advanced solutions, such as automated coagulation assays, to enhance the accuracy, efficiency, and consistency of direct oral anticoagulant level monitoring in clinical laboratories. Automated coagulation assays are laboratory tests performed by machines that measure how quickly blood clots, aiding in the diagnosis of bleeding or clotting disorders. For instance, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, introduced three new coagulation tests specifically tailored for Factor Xa inhibitors. These tests improve clinicians’ capability to accurately evaluate the anticoagulation status of patients taking direct Factor Xa inhibitors like rivaroxaban and apixaban. They support clinical decision-making by precisely measuring the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin in critical scenarios such as bleeding, overdose, or urgent surgery. Utilizing Roche’s reagent cassette technology on cobas t analyzers, these automated tests deliver high-quality results, minimize manual handling, and streamline laboratory workflow efficiency.
Direct Oral Anticoagulants (DOACs) Device Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the direct oral anticoagulants (doacs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., DOASENSE GmbH.
View The Full Direct Oral Anticoagulants (DOACs) Device Market Report:
Direct Oral Anticoagulants (DOACs) Device Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2025. The regions covered in the direct oral anticoagulants (doacs) device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
